Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 8/20 | 0.56 |
| ▸ | EGFR | P00533 | 5/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | AHR | P35869 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15154495 | 0.94 | MAPT (0.51) | SRCEGFRMAOBSMN1; SMN2MAPT | |
| SCHEMBL11983230 | 0.90 | SRC (0.64) | SRCEGFRMAOBSMN1; SMN2MAPT | |
| SCHEMBL11983179 | 0.87 | SRC (0.56) | SRCEGFRMAOBSMN1; SMN2MAPT | |
| SCHEMBL15154505 | 0.87 | EGFR (0.62) | SRCEGFRMAPTNPC1RAB9A | |
| SCHEMBL15154429 | 0.86 | NPC1 (0.59) | SRCEGFRSMN1; SMN2MAPTNPC1 | |
| SCHEMBL15154120 | 0.85 | SRC (0.48) | SRCEGFRSMN1; SMN2NPC1RAB9A | |
| SCHEMBL15154108 | 0.85 | EGFR (0.60) | SRCEGFRSMN1; SMN2MAPTNPC1 | |
| SCHEMBL10674889 | 0.84 | EGFR (0.61) | SRCEGFRSMN1; SMN2MAPTNPC1 | |
| SCHEMBL15154173 | 0.83 | SRC (0.55) | SRCEGFRMAOBSMN1; SMN2MAPT | |
| SCHEMBL15153996 | 0.81 | ALDH1A1 (0.40) | SMN1; SMN2MAPTALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962598-B2 | 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as AHR activators | IMMUNAHR AB (SE) | 2015-02-24 | — | — | US | claimed |
| EP-2627638-A1 | 1,2-DIHYDRO-4-HYDROXY-2-OXO-QUINOLINE-3-CARBOXANILIDES AS AHR ACTIVATORS. | Immunahr AB (SE) | 2013-08-21 | — | — | EP | claimed |
| US-20130203703-A1 | 1,2-DIHYDRO-4-HYDROXY-2-OXO-QUINOLINE-3-CARBOXANILIDES AS AHR ACTIVATORS | IMMUNAHR AB (SE) | 2013-08-08 | — | — | US | claimed |
| WO-2012050500-A1 | 1,2-DIHYDRO-4-HYDROXY-2-OXO-QUINOLINE-3-CARBOXANILIDES AS AHR ACTIVATORS. | PETTERSSON LARS (SE) | 2012-04-19 | — | — | WO | claimed |
| US-8962598-B2 | 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as AHR activators | IMMUNAHR AB (SE) | 2015-02-24 | — | — | US | disclosed |
| US-20130203703-A1 | 1,2-DIHYDRO-4-HYDROXY-2-OXO-QUINOLINE-3-CARBOXANILIDES AS AHR ACTIVATORS | IMMUNAHR AB (SE) | 2013-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203703-A1 | 1,2-DIHYDRO-4-HYDROXY-2-OXO-QUINOLINE-3-CARBOXANILIDES AS AHR ACTIVATORS | AHR, HRH4, ARNT | SRC 2173/4885EGFR 826/4885MAOB 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.